Published in Clin Breast Cancer on April 01, 2012
The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging (2013) 1.14
Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology. J Surg Oncol (2013) 0.87
Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer. Oncol Lett (2012) 0.85
Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy. Biomed Res Int (2013) 0.79
Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors. Theranostics (2016) 0.78
New researches and application progress of commonly used optical molecular imaging technology. Biomed Res Int (2014) 0.78
Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. Oncologist (2017) 0.75
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases (2015) 0.75
The Changing World of Breast Cancer: A Radiologist's Perspective. Invest Radiol (2015) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol (1997) 6.35
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (2001) 5.74
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer (2002) 2.18
Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol (2005) 2.05
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol (2002) 2.00
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol (2004) 1.69
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res (2011) 1.69
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol (2011) 1.59
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer (2007) 1.53
Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer (2010) 1.48
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer (2008) 1.44
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer (2010) 1.44
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol (2008) 1.42
Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology (2009) 1.42
Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol (2003) 1.32
Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol (2008) 1.27
The prognostic importance of triple negative breast carcinoma. Breast (2008) 1.27
Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol (2008) 1.27
Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast (2009) 1.15
Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2008) 1.15
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol (2006) 1.12
Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging (2011) 1.11
Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J (2006) 1.11
Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol (1997) 1.10
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol (2004) 1.07
Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol (2002) 1.06
Who should have breast magnetic resonance imaging evaluation? J Clin Oncol (2008) 1.04
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer (2003) 1.04
Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol (2009) 1.00
Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol (2007) 0.99
Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2008) 0.97
Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J (2006) 0.95
Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer (2008) 0.94
Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol (2007) 0.94
Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. Med Oncol (2008) 0.92
Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast (2005) 0.89
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg (2008) 0.87
[Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI?]. Radiologe (2007) 0.81
Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. J Clin Oncol (2007) 0.79
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. Ned Tijdschr Geneeskd (2008) 0.77
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis (2013) 3.10
Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys (2008) 2.84
Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) (2011) 2.62
Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res (2003) 2.61
The California breast density information group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation. Radiology (2013) 2.27
Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg (2008) 2.19
Identifying minimally acceptable interpretive performance criteria for screening mammography. Radiology (2010) 2.06
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
Quantitative analysis of lesion morphology and texture features for diagnostic prediction in breast MRI. Acad Radiol (2008) 1.70
Nutrition impacts the prevalence of peripheral arterial disease in the United States. J Vasc Surg (2008) 1.62
Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A (2011) 1.62
Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood (2006) 1.58
Pathological complete response in triple negative poorly differentiated invasive ductal breast carcinoma detected during pregnancy. J Clin Oncol (2007) 1.51
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Whole breast lesion detection using naive bayes classifier for portable ultrasound. Ultrasound Med Biol (2012) 1.44
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer (2008) 1.44
Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA (2006) 1.40
Professional and economic factors affecting access to mammography: a crisis today, or tomorrow? Results from a national survey. Cancer (2005) 1.38
Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy. Philos Trans A Math Phys Eng Sci (2011) 1.38
Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis (2014) 1.36
Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat (2003) 1.34
Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology (2009) 1.34
Dependent pooling: a contrast-enhanced sign of cardiac arrest during CT. AJR Am J Roentgenol (2002) 1.27
Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol (2008) 1.27
Survey of radiology residents: breast imaging training and attitudes. Radiology (2003) 1.26
Diagnostic accuracy of digital mammography in patients with dense breasts who underwent problem-solving mammography: effects of image processing and lesion type. Radiology (2003) 1.24
Selection of diagnostic features on breast MRI to differentiate between malignant and benign lesions using computer-aided diagnosis: differences in lesions presenting as mass and non-mass-like enhancement. Eur Radiol (2009) 1.24
Behavioral, histological, and ex vivo magnetic resonance imaging assessment of graded contusion spinal cord injury in mice. J Neurotrauma (2007) 1.24
A new bias field correction method combining N3 and FCM for improved segmentation of breast density on MRI. Med Phys (2011) 1.23
TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res (2008) 1.23
Re: Changes in breast cancer detection and mammography recall rates after the introduction of a computer-aided detection system. J Natl Cancer Inst (2004) 1.20
Diagnosis of hepatic tumors with texture analysis in nonenhanced computed tomography images. Acad Radiol (2006) 1.15
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol (2002) 1.15
Duodenocaval fistula: a late complication of retroperitoneal irradiation and vena cava replacement. Ann Vasc Surg (2004) 1.13
MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging (2007) 1.13
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res (2009) 1.12
Multicentric aggressive angiomyolipomas: a rare form of PEComas. AJR Am J Roentgenol (2006) 1.12
Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res (2013) 1.09
Guidelines for pediatric cancer centers. Pediatrics (2004) 1.09
Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient. Acad Radiol (2010) 1.09
VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest (2003) 1.05
Quantitative analysis of breast parenchymal patterns using 3D fibroglandular tissues segmented based on MRI. Med Phys (2010) 1.05
Impact of skin removal on quantitative measurement of breast density using MRI. Med Phys (2010) 1.04
The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun (2006) 1.04
Regional quantification of white matter hyperintensity in normal aging, mild cognitive impairment, and Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 1.04
Mild cognitive impairment: apparent diffusion coefficient in regional gray matter and white matter structures. Radiology (2006) 1.03
Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon. Cancer (2009) 1.02
Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. J Neurosci (2004) 1.01
Quantitative correlation between (1)H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging (2007) 1.01
An integrative modeling approach to elucidate suction-feeding performance. J Exp Biol (2012) 1.00
Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging (2008) 1.00
The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun (2006) 0.99
Comparison of breast density measured on MR images acquired using fat-suppressed versus nonfat-suppressed sequences. Med Phys (2011) 0.99
Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation. Radiology (2010) 0.98
Microsatellite instability in Japanese vs European American patients with gastric cancer. Arch Surg (2002) 0.97
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology (2011) 0.97
Managing anemia in a pediatric office practice: Part 2. Pediatr Rev (2002) 0.97
Managing anemia in pediatric office practice: Part 1. Pediatr Rev (2002) 0.97